



K-2

## Novel Targets for Treatment of Tuberculosis



**Dr. Shridhar Narayanan,**

Vice President and Head, Infection iScience , Astra Zeneca, Bangalore

Email: shridhar.narayanan@astrazeneca.com

---

*Dr. Shridhar Narayanan presently Vice President and Head of Innovative Science for the Infection Innovative Medicines group at AstraZeneca, India. He has more than 10 years of drug discovery and development experience in Indian pharmaceutical industry in various therapeutic areas. Most recently, Dr. Shridhar has been the Executive Vice President-Discovery Biology and Drug Development at Orchid Chemicals and Pharmaceuticals. In this role, Dr. Shridhar has been responsible for the design and implementation of the scientific and business strategy for drug discovery and development across therapeutic areas, managing a team of scientists in biology, DMPK, safety pharmacology, and regulatory toxicology and clinical development. Throughout his career, Dr. Shridhar has overseen Discovery and Development of about 15 clinical candidates, the farthest being in Phase 3 clinical trials. He has also executed out-licensing deals with major pharma as well as in-licensing of candidates (NCE/NBE) which are in active development. Dr. Shridhar has been a member of joint research committees, academic and industry collaborations and has served as a Ph.D. guide for 3 Ph.D. students.*

---

### **Abstract:**

The talk will focus on the current state of TB therapy, novel targets and combinations under investigation for the treatment of tuberculosis. The contribution of AstraZeneca to neglected disease research in general and tuberculosis in particular will be highlighted.

